During the course of searching for antiviral agents from Chinese medicinal herbs, we found that the supercritical fluid extract (SFE) of Centipeda minima possessed good in vitro antiviral activity against influenza virus A/Puerto Rico/8/34 H1N1 (PR8). Bioassay-guided isolation and identification led to the isolation from this extract of seven pseudoguaianolides (1-7). These, as well as nine other sesquiterpene lactones (8-16) previously isolated from this herb were all tested for their anti-PR8 activity using both the cytopathogenic effect (CPE) reduction and cell counting kit 8 (CCK8) assays. As a result, eight pseudoguaianolides (1-8) possessing an α,β-unsaturated cyclopentenone moiety showed antiviral activity against PR8 to different extents. Of the active compounds, brevilin A (4) exhibited the strongest anti-PR8 activity, with an IC 50 value much lower than that of the positive control ribavirin. Mechanistic study revealed that brevilin A affected the intracellular replication of PR8 via downregulating the expression of viral M2 protein. All these results suggest the potential application of the pseudoguaianolides containing an α,β-unsaturated cyclopentenone moiety (e.g. brevilin A) in the treatment of influenza virus infection.
Influenza A viruses (IAV), the most common respiratory pathogen that is responsible for seasonal epidemics, pose a continuing threat to human health [1] . Each year, seasonal influenza virus infection results in approximately 3 to 5 million cases of severe illness and 225,000 to 500,000 deaths worldwide [2] . Currently, only two classes of FDA-approved antivirals against IAV are available; these are M2 ion channel inhibitors (e.g. amantadine and rimantadine) and neuraminidase (NA) inhibitors (e.g. oseltamivir, zanamivir, laninamivir and peramivir) [3] . The former is no longer recommended for the treatment of IAV infection because their drug-resistant virus variants have become widespread, while the application of the latter also faces the risk of generation and spread of drug-resistances [4] . Therefore, novel antiviral agents against IAV are required for development.
Centipeda minima (L.) A. Br. Ascher. (Compositae), an annual herb, is widely distributed in China, eastern tropical Asia and Australia. The whole herb of C. minima has been traditionally used as a Chinese folk medicine for the treatment of colds, headache, nasal allergies, asthma, and coughs [5] . Studies showed that C. minima had anti-tumor [6a-6c] [6a] , and sesquiterpene lactones (SLs) [6b-6k] as the active components.
During the course of screening for antiviral agents from Chinese medicinal herbs, we found that the supercritical fluid extract (SFE) of C. minima showed good protection against MDCK cell infection by influenza virus A/Puerto Rico/8/34 H1N1 (PR8) with an IC 50 value of 2.5 μg/mL (CPE reduction assay). Thus, its extract was subjected to bioassay-guided isolation and identification, which led to the isolation of seven pseudoguaianolides (1) (2) (3) (4) (5) (6) (7) . By comparing their obtained spectroscopic data with values reported previously, these compounds were identified as arnicolide D (1) [7a, 7b] 
, and arnicolide B (7) [7b] . The seven pseudoguaianolides (1) (2) (3) (4) (5) (6) (7) isolated in the present study, in combination with nine SLs previously isolated from this herb in our lab [6c], including five pseudoguaianolides [plenolin (8) , helenalin (9), minimolide A (12), minimolide C (13) and minimolide D (14)] and four guaianolides [florilenalin-2-O-angelate (10), florilenalin-2-O-isobutyrate (11) , minimolide E (15) and minimolide F (16) ], were evaluated for their antiviral activity against PR8 using the CPE reduction and CCK8 assays. As a result, the pseudoguaianolides (1) (2) (3) (4) (5) (6) (7) (8) , containing an α,β-unsaturated cyclopentenone moiety, exhibited different levels of antiviral activity against PR8, with IC 50 values ranging from 1.8 ± 0.6 to 11.6 ± 1.3 μM ( Table 1 ). The structures of these eight active pseudoguaianolides only differ in the side chain of C-6.
SLs are regarded as important naturally occurring compounds with a wide range of biological activities [8] . Currently, only a few sesquiterpenes have been reported to possess antiviral activities, i.e. against HBV [9a-9c] . The α-methylene-γ-lactone moiety is generally accepted as an important functional group responsible for the cytotoxic, antitumor, and anti-inflammatory effects of sesquiterpene lactones [8] . However, in this study, all the SLs containing an α-methylene-γ-lactone moiety (9-11, 13-16) lacked inhibitory activity against PR8. It is noteworthy that 3.5 ± 1.6 26.5 ± 1.6 7.5 6 5.6 ± 0.8 38.9 ± 3.3 6.9 7 2.1 ± 0.5 42.0 ± 0.7 9.4 8 4.6 ± 1.1 36.7 ± 1.2 8.1
Data shown are the mean ± SD for at least three independent experiments. a IC 50 , the concentration required to protect cells from the cytopathogenic effect of PR8 by 50%. b CC 50 , cytotoxic concentration required to reduce cell viability by 50% for uninfected MDCK cells by MTT assay. c SI, selectivity index, the CC 50 /IC 50 ratio. d Not determined. e Ribavirin, the positive control.
helenalin (9), possessing both α,β-unsaturated cyclopentenone and α-methylene-γ-lactone moieties, had the strongest cytotoxic effect among these SLs, but did not show anti-PR8 activity under its noncytotoxic concentration. In this study, we report for the first time the antiviral activity of the pseudoguaianolides against IAV, and found that α,β-unsaturated cyclopentenone is the functional moiety essential for their antiviral activity.
As brevilin A (4) showed the strongest antiviral activity against PR8, with an IC 50 value of 1.8 ± 0.6 μM and a SI value of 13.5, it was chosen to explore the possible antiviral mechanisms against PR8. It showed significant and concentration-dependent inhibitory activity against PR8 under the non-cytotoxic concentration in the CPE reduction and CCK8 assays. Besides, at the concentration of 8 μM, the inhibition rates of brevilin A and ribavirin against PR8 were 100% and 38%, respectively ( Figure 2 ). To elucidate the inhibitory activity of brevilin A on either viral extracellular or intracellular replication, we respectively examined the effects of brevilin A on pretreatment, co-treatment and post-treatment stages by changing the time of addition and removal of brevilin A. Brevilin A at 8 μM showed notably anti-PR8 activity on co-treatment and post-treatment stages, and the inhibition rates of influenza infection reached 100% compared with the virus control, while pretreatment had minimal viral inhibitory activity ( Figure 3 ). These data indicated that brevilin A exhibited its antiviral activity after virus entry into the cells. . In the present study, the hemagglutination inhibition (HI) assay demonstrated that brevilin A could not interfere with the HA receptor-binding activity (data not shown), and further confirmed that brevilin A had no effect on the early stage of viral replication. Moreover, we also found that the antiviral activity mode of brevilin A was not related to its effect on either NA-mediated virus release (data not shown) or viral polymerase activity ( Figure 4A ). However, Western Blot assay showed that brevilin A slightly reduced the protein expressions of NP and M1, but markedly inhibited the protein expression of M2 in comparison with the virus control ( Figure 4B ). M2 synthesis in influenza virus-infected MDCK cells occurred at about 4.5 h post-infection, and reached its highest levels at approximately 6 h post-infection [11] . Accordingly, our results indicated that brevilin A mainly affects the late stage of the viral life cycle and may influence the replication of influenza virus through inhibition of the expression of viral M2 protein.
Figure 4:
Brevilin A hardly influenced viral RNA polymerase activity (A), but inhibited viral protein expression (B). The statistical significance was determined using Students's t-test (ns, non-significant).
In conclusion, this study firstly demonstrated that the antiviral constituents of the SFE of C. minima against PR8 were the pseudoguaianolides with an α,β-unsaturated cyclopentenone moiety. Brevilin A exhibited better antiviral activity against PR8 than the positive control ribavirin. This compound mainly influences the late stage of the viral life cycle and blocks viral replication through inhibiting the synthesis of M2 protein. These data suggest the potential application of the pseudoguaianolides (e.g. brevilin A) in the treatment of influenza virus infection.
Experimental
Plant material: The whole herb of C. minima was purchased from Er Tian Tang drugstore (Guangzhou, China), and was authenticated by Prof. Guang-Xiong Zhou, College of Pharmacy, Jinan University (Guangzhou, China). A voucher specimen (No.20130925) was deposited in the Institute of Traditional Chinese Medicine and Natural Products, College of Pharmacy, Jinan University (Guangzhou, China).
Extraction and isolation:
The dried and powdered whole herb (200 mesh sieve) of C. minima (2.0 kg) was extracted with CO 2 in a supercritical extraction unit at a pressure of 20 MPa at 40ºC for 2 h, and a flow rate of CO 2 of 20 L/h. The extract (70.0 g) was absorbed onto silica gel and subjected to silica gel CC eluting with a gradient of light petroleum/ethyl acetate (100:0 → 0:100, v/v). Each fraction was collected and examined on silica gel TLC plates with a solvent system of light petroleum and ethyl acetate in the ratio of either 8:2 or 7:3. Fractions with similar Rf values were combined and concentrated to yield 6 fractions, namely Fr.1 (12.4 g), Fr.2 (6.9 g), Fr.3 (5.3 g), Fr.4 (4.9 g), Fr.5 (7.2 g) and Fr.6 (10.5 g). The antiviral activity of all fractions was evaluated by both CPE and CCK8 assays. Fr.5 was selected for further separation because it showed antiviral activity. The separation of Fr.5 was performed using silica CC and eluting with a gradient of light petroleum/ethyl acetate (9:1 → 7:3, v/v) to yield 5 sub-fractions, namely sub-Fr.1 (0.2 g), subFr.2 (0.1 g), sub-Fr.3 (5.1 g), sub-Fr.4 (0.7 g) and sub-Fr.5 (0.5 g).
Only sub-Fr.3 showed antiviral activity, and this was further purified by preparative HPLC (MeOH/H 2 O, 1:1) to afford 1 (82.4 mg), 2 (40.5 mg), 3 (10.6 mg), 4 (58.4 mg, purity > 95% by HPLC), 5 (41.6 mg), 6 (51.4 mg), 7 (22.8 mg) and a mixture of 4 and 5 (683.6 mg).
Cytotoxicity assay:
The cytotoxicity of test samples was determined by the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT; Sigma-Aldrich, USA) assay, as previously reported [12a] .
Viral inhibition assay:
The antiviral activity of the fractions and pure compounds against PR8 was evaluated using the following protocol. In the primary screening, the antiviral activity was evaluated by CPE reduction assay, as described previously, with some modifications [12b] . Briefly, confront MDCK cells in 96-well plates were infected with PR8 (100 TCID 50 , 100 μL) for 1 h, after removal of the virus inoculum, washed twice with PBS, and then treated with two-fold diluted test samples. The maximal noncytotoxic concentration (MNCC) of the test samples was used as the highest concentration. After incubation for 48-72 h, the morphology of the cells was observed under a light microscope (Olympus Microscope DP70, Japan) daily, and scored for CPE condition. When the CPE of the virus control reached > 75%, the culture supernatant was removed and covered with fresh maintenance medium containing 10% CCK8 solution. After another 0.5-2 h incubation, the absorbance was recorded on a microplate reader at 450 nm with a reference wavelength of 650 nm. The virus inhibition (%) was calculated by the equation: virus inhibition (%) = [(A sample 450 -A virus 450 ) / (A mock 450 -A virus 450 )] × 100; where, A mock 450 was the absorbance without virus infection, A sample 450 was the absorbance with virus infection and drug treatment; and A virus 450 was the absorbance with virus infection, but without drugs. The concentrations required to protect cells from the cytopathogenic effect of PR8 by 50% (IC 50 ) were calculated through nonlinear regression analysis (sigmoidal dose-response variable slope) using GraphPad Prism 8.5 software. The selective index (SI) was calculated as the ratio of CC 50 to IC 50 .
Time of addition assay: MDCK cells were seeded in 96-well plates at 37ºC overnight to about 80% confluency. The supernatants were removed, and the cells washed twice with PBS. Brevilin A (8 μM) was added to the cells before 2 h of viral infection (pretreatment), at the same time as infection (co-treatment), and 1 h after infection (posttreatment). After removal of the supernatants and washing with PBS, the fresh medium with or without brevilin A was added to the cells. After incubation for 48 h, the cell viability was measured by CCK8 assay.
Hemagglutination inhibition (HI) assay:
The HI assay was performed to evaluate the inhibitory activity of the test compound on HA-mediated hemagglutination of chicken red blood cell (cRBC) solutions [12c].
Neuraminidase inhibition (NI) assay: Inhibition of NA enzymatic activity was assessed using a Neuraminidase Inhibitors Screen Kit (Beyotime Institute of Biotechnology, China) according to the manufacturer's instructions.
Cell-based influenza polymerase assay: To determine whether brevilin A inhibited polymerase activity of PR8, a cell-based influenza polymerase assay was performed with a dual-luciferase reporter assay system, as previously described [12d] . The four plasmids PB2, PB1, PA, and NP (25 ng each) and of PR8 were cotransfected with Lipofectamine 2000 (Invitrogen, Thermo-Fisher, USA) into 293T cells together with polI-fluc (10 ng, expressing firefly luciferase) and an internal control plasmid pRL-TK (5 ng, expressing Renilla luciferase, Promega) at 37ºC in 5% CO 2 . After transfection for 4 h, brevilin A at various concentrations was added into the cells for 24 h. Cells were harvested and both firefly luciferase and Renilla luciferase expression were measured by the Dual-Luciferase® Reporter assay system (Promega, USA).
Western Blot analysis: MDCK cells (1× 10
5 cell/mL) were seeded into a 10 cm dish for incubating at 37ºC overnight under 5% CO 2 . The cells were washed twice with PBS, and then infected with PR8 (MOI = 1) containing various concentrations of either brevilin A or ribavirin. The cells were harvested after another 10 h (about one life cycle of IAV), then washed twice with PBS and lysed with RIPA buffer containing protease inhibitors. The lysates were incubated for 20 min on ice and then centrifuged at 12,000 g for 15 min at 4ºC. The supernatants were collected and the protein concentrations determined with Bio-Rad Protein Assay Kits (Bio-Rad, USA).
Equal amounts of proteins were boiled in SDS buffer for 5 min, and then separated by SDS-PAGE, and transferred onto nitrocellulose membranes. After being blocked in Tris-buffered saline containing 0.1% Tween 20 (TBST, v/v) and 5% bovine serum albumin (BSA, w/v) at room temperature for 2 h, the membranes were stained with primary antibodies at 4ºC overnight. The membranes were washed by TBST, and then secondary antibodies were conjugated to horseradish peroxidase. Membranes were developed by using an enhanced chemiluminescence system. Statistics: Data were analyzed using two-way ANOVA. Results are expressed as the mean ± standard deviation (S.D.) with significance at p < 0.05.
Supplementary data:
The HPLC chromatograms for the supercritical fluid extract of C. minima showing compounds 1-7, as well as HR-ESI-MS, UV, IR, and 1 H, 13 C NMR spectra for compounds 1-7 are available.
